Arcus Biosciences
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2015-01-01
- Employees
- 577
- Market Cap
- -
- Website
- http://www.arcusbio.com
- Introduction
Arcus Biosciences, Inc. engages in the development and commercialization of immunotherapies. It competes in the segments of the pharmaceutical, biotechnology and other related markets that develop immunotherapies for the treatment of cancer. The company was founded by Terry J. Rosen and Juan Carlos Jaen in 2015 and is headquartered in Hayward, CA.
Casdatifan Plus Cabozantinib Combination Shows 46% Response Rate in Kidney Cancer Trial
Arcus Biosciences reported a 46% confirmed overall response rate for the casdatifan plus cabozantinib combination in patients with clear cell renal cell carcinoma who had progressed on prior immunotherapy.
Arcus's HIF-2α Inhibitor Shows Promise in Kidney Cancer, Despite Gilead's Exit
Arcus Biosciences' casdatifan demonstrates superior efficacy profile compared to Merck's Welireg in Phase I/Ib kidney cancer trial, showcasing potential advancement in HIF-2α inhibition.
Arcus Biosciences to Present Casdatifan Monotherapy Data in Advanced Kidney Cancer at ASCO GU 2025
Arcus Biosciences will showcase safety and efficacy data from the ARC-20 study evaluating casdatifan in previously treated kidney cancer patients at the 2025 ASCO GU Symposium.
Recent Clinical Trial Failures: Roche, AbbVie, and Cassava Sciences Face Setbacks
Roche's anti-TIGIT drug, tiragolumab, failed to demonstrate a life-extending benefit in a Phase 3 trial for non-small cell lung cancer, raising concerns about the TIGIT inhibitor class.
Adenosine Antagonists Show Promise in Clinical Trials for Cancer and COPD
• Adenosine antagonists are under investigation for novel therapeutic applications in neurodegenerative diseases, oncology, and cardiovascular disorders. • Several companies, including Arcus Biosciences and Corvus Pharmaceuticals, are advancing adenosine antagonists through clinical trials to improve treatment landscapes. • Clinical trials are evaluating drugs like etrumadenant, ciforadenant and PBF-680 in various phases for conditions like colorectal cancer, prostate cancer and COPD.
Domvanalimab Plus Zimberelimab Improves Overall Survival in Advanced NSCLC
The combination of domvanalimab and zimberelimab demonstrated a statistically significant improvement in overall survival (OS) compared to zimberelimab alone in advanced NSCLC patients.
Casdatifan Shows Promise in Metastatic Clear Cell Renal Cell Carcinoma
Casdatifan, a HIF-2α inhibitor, demonstrated a 34% objective response rate in heavily pretreated patients with metastatic clear cell renal cell carcinoma (ccRCC).
Arcus Biosciences and AstraZeneca Collaborate to Evaluate Novel Combination Therapy for Clear Cell Renal Cell Carcinoma
Arcus Biosciences and AstraZeneca are collaborating to evaluate casdatifan, a HIF-2a inhibitor, with volrustomig, a PD-1/CTLA-4 bispecific antibody, for ccRCC treatment.
Gilead's $27 Billion Oncology Transformation: Strategic Deals Reshape Company's Future
• Gilead Sciences has executed over $27 billion worth of strategic oncology deals in 2020, marking its most aggressive push yet to establish leadership in cancer treatment. • Under new leadership, including CEO Daniel O'Day and CFO Andrew Dickinson, Gilead has acquired Immunomedics for $21 billion and made significant investments in multiple biotech companies focused on immuno-oncology. • The company aims to balance its traditional antiviral portfolio with a strong oncology presence, highlighted by the acquisition of Trodelvy, while maintaining approximately $11 billion for future strategic investments.